YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company Logo The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%;…
Image source: The Motley Fool. DATE Monday, Aug. 10, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Investor Relations - Mary Conway President and Chief Executive Officer - Everett Cunningham Chief Financial Officer - Jason Faessler Senior Vice Pr…
Key Points Interested in Quanterix Corporation? Here are five stocks we like better. Quanterix is restructuring its sales organization into dedicated teams for spatial biology, Simoa products and clinical-trial services after determining t…
Key Points Interested in Quanterix Corporation? Here are five stocks we like better. Quanterix cut its 2026 outlook after second-quarter revenue of $32.9 million fell $3 million short of guidance amid broad market weakness and commercial e…
Major earnings expected before the bell on Monday include: * Barrick Mining Corporation (B [https://seekingalpha.com/symbol/B]) * Medical Properties Trust (MPT [https://seekingalpha.com/symbol/MPT]) * Seadrill Limited (SDRL [https://seekin…
* Quanterix (QTRX [https://seekingalpha.com/symbol/QTRX]) is scheduled to announce Q2 earnings results on Monday, August 10th, before market open. * The consensus EPS Estimate is -$0.41 [https://seekingalpha.com/symbol/QTRX/earnings/estima…
Company Logo Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive and structured analysis of 590+ bi…
In trading on Tuesday, medical instruments & supplies shares were relative laggards, down on the day by about 2.5%. Helping drag down the group were shares of Enovis, off about 11.2% and shares of Quanterix off about 9% on the day. Also la…
BILLERICA, Mass., June 03, 2026--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will pa…
(RTTNews) - Monday's top gainers include Turn Therapeutics following its interim analysis findings from an atopic dermatitis study; Conexeu Science on progress in its B.R.E.A.S.T. bioprinting program; LIXTE Biotechnology and its strategic…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Tempus AI (NasdaqGS:TEM) and Lucent Diagnostics, a Quanterix company, are teaming up to bring an AI-enabled care pathwa…
Image source: The Motley Fool. Date Wednesday, May 6, 2026 at 4:30 p.m. ET Call participants President and Chief Executive Officer — Everett Cunningham Chief Financial Officer — Vandana Sriram Head of Investor Relations — Joshua Young Need…
Image source: The Motley Fool. Date March 2, 2026 Call participants President and Chief Executive Officer — Everett Cunningham Chief Financial Officer — Vandana Sriram Head of Investor Relations — Joshua Young Need a quote from a Motley Fo…
Earnings Call Insights: Quanterix Corporation (QTRX) Q4 2025 MANAGEMENT VIEW * Everett Cunningham, President and CEO, introduced himself to investors, emphasizing his background in healthcare and commercial strategy from prior roles at Ill…
Major earnings expected after the bell on Monday include: * Plug Power (PLUG [https://seekingalpha.com/symbol/PLUG]) * Archer Aviation (ACHR [https://seekingalpha.com/symbol/ACHR]) * Credo Technology Group Holding Ltd (CRDO [https://seekin…
* Quanterix (QTRX [https://seekingalpha.com/symbol/QTRX]) is scheduled to announce Q4 earnings results on Monday, March 2nd, after market close. The consensus EPS Estimate is -$0.48 [https://seekingalpha.com/symbol/QTRX/earnings/estimates]…
Quanterix QTRX recently announced the submission of a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test designed to aid in the evaluation of patients with cognitive symptoms for possible Alzheimer’s dise…
MENLO PARK, Calif., January 08, 2026--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson’s disease and other neurodegenerative dis…
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director BILLERICA, Mass., November 20, 2025--(BUSINESS WIRE)--Quanterix Corporation ("Qu…
(RTTNews) - Quanterix Corp (QTRX) revealed Loss for its third quarter that increased from last year and missed the Street estimates. The company's earnings totaled -$33.52 million, or -$0.73 per share. This compares with -$8.35 million, or…
Earnings Call Insights: Quanterix Corporation (QTRX) Q3 2025 MANAGEMENT VIEW * Masoud Toloue, President and CEO, stated that "we're pleased with how we executed in the third quarter, especially given the significant integration work underw…
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago. These figures are adjusted for non-recurring item…
[Blood sample for Alzheimer test] jarun011/iStock via Getty Images * Shares of Quanterix Corp. are up ~4% in Wednesday morning trading after CMS' recently released preliminary Clinical Lab Fee Schedule listed the company's LucentAD Alzheim…
Investing.com - Canaccord Genuity downgraded Quanterix Corp. (NASDAQ:QTRX) from Buy to Hold and slashed its price target to $5.00 from $12.00, citing lack of near-term visibility and catalysts. The stock has already fallen over 21% in the…
* Quanterix press release [https://seekingalpha.com/pr/20194280-quanterix-releases-financial-results-for-the-second-quarter-of-2025] (NASDAQ:QTRX [https://seekingalpha.com/symbol/QTRX]): Q2 GAAP EPS of -$0.77 misses by $0.36. * Revenue of…
[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDA…
Quanterix Corp (NASDAQ:QTRX), a life sciences company with annual revenue of $135.69 million, reported Monday that it has committed to a plan to terminate certain executives at its recently acquired subsidiary, Akoya Biosciences, Inc. The…
BILLERICA, Mass., July 11, 2025--(BUSINESS WIRE)--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025…
(RTTNews) - Quanterix Corporation (QTRX), a leader in ultra-sensitive biomarker detection, has completed its acquisition of Akoya Biosciences, Inc., a strategic move that positions the combined company as a leading force in early disease d…
Quanterix Corporation (NASDAQ:QTRX) has completed its acquisition of Akoya Biosciences , Inc. (NASDAQ:AKYA), a company with a market capitalization of $64.4 million and annual revenue of approximately $80 million, according to a statement…
BILLERICA, Mass. - Quanterix Corporation (NASDAQ:QTRX) announced Tuesday it has completed its previously announced acquisition of Akoya Biosciences, Inc., creating what the company describes as a scaled leader in early disease detection fo…
[Wide Angle Shot of a Clean and Organized Modern Laboratory] Tom Werner * Several life sciences tools companies closed noticably higher Wednesday following a report that the NIH has issued a memo not to cancel funding for any more research…
BILLERICA, Mass. - Quanterix Corporation (NASDAQ:QTRX), a medical technology company with a market capitalization of $237.64 million, announced Monday that its HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registratio…
Canaccord Genuity reiterated its Buy rating and $12.00 price target on Quanterix Corp. (NASDAQ:QTRX) following discussions with the company’s management about growth drivers and its pending merger with Akoya. According to InvestingPro data…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Monday, AppFolio's, Timothy K. Bliss, made…
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services R…